Top news from SGO: Updates in endometrial, ovarian, cervical cancer and more
Click Here to Manage Email Alerts
The Healio Editors compiled a list of recent news from the Society of Gynecologic Oncology Annual Meeting held from March 25-28, 2023.
Highlights include new data on endometrial cancer drugs; studies on pembrolizumab in endometrial cancer, post-discharge complications after debulking surgery, neoadjuvant olaparib for women with germline-mutant ovarian cancer, and more.
Read these articles, and others, below, in no particular order.
Dostarlimab study ‘will change the lives of our patients’ with endometrial cancer
Dostarlimab plus carboplatin significantly increased progression-free survival among women with primary advanced or recurrent endometrial cancer. Read more
Study of pembrolizumab regimen in endometrial cancer yields ‘encouraging new finding’
The addition of pembrolizumab to chemotherapy significantly extended progression-free survival for women with advanced or recurrent endometrial cancer. Read more
Symptom tracking tool identifies post-discharge complications after debulking surgery
A digital tool that tracks patient-reported symptoms helped identify post-discharge complications among women with gynecologic cancer who underwent debulking surgery, according to retrospective study results. Read more
Niraparib maintenance therapy fails to significantly extend overall survival in recurrent ovarian cancer
Niraparib did not significantly extend overall survival among women with recurrent ovarian cancer, according to long-term follow-up results of the ENGOT-OV16/NOVA trial. Read more
Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial. Read more
Nab-paclitaxel regimen active in locally advanced cervical cancer
The addition of nab-paclitaxel to cisplatin-based concurrent chemoradiotherapy appeared effective for women with locally advanced cervical cancer, according to prospective study results. Read more